Results summaries for study participants

We work with regulators to help share clinical trial information with our participants.

As part of our patient focused drug development here at AbbVie, we strive to provide summary information about completed trials in an easy and understandable manner while upholding our commitments to trade associations principles and preparedness for the upcoming European Union (EU) Clinical Trials Regulation requirements.

A summary of clinical trial results for laypersons, referred to as a lay summary of results or plain language summary (PLS), is a brief description of the clinical trial results in everyday language that is understandable to people who do not have a medical or scientific background. In 2019, AbbVie publicly disclosed Plain Language Summaries (PLS) of results for phase 2-4 clinical trials completed in 2018 for already approved products and or indications. In 2020, the set of studies in scope includes interventional trials completed in 2019.

See below for available summaries:

Virology

Study ID/Title Condition Description
M15-592
A study to learn how effective and safe a medicine containing glecaprevir and pibrentasvir works to treat Asian adult patients with long-lasting hepatitis C genotype 1 to 6 infection without liver cirrhosis (scarring of the liver) Hepatitis C virus

Trial dates:
Oct 2017 – Feb 2019

Last modified:
Dec 2019

Available languages:
Chinese, English, Korean

M15-593
A study to learn how effective and safe a medicine containing glecaprevir and pibrentasvir works to treat Asian adult patients with long-lasting hepatitis C genotype 1 to 6 infection with compensated liver cirrhosis (scarring of the liver while the liver is still able to function) Hepatitis C virus

Trial dates:
Sept 2017 – Feb 2019

Last modified:
Jan 2020

Available languages:
Chinese, English, Korean

M16-126
A study to learn how effective and safe a medicine containing glecaprevir and pibrentasvir works to treat adult patients with long-lasting hepatitis-C genotype 5 or 6 infection Hepatitis C virus

Trial dates:
Jan 2017 – Aug 2018

Last modified:
Sep 2019

Available languages:
EnglishFrench, French Canadian, Vietnamese

M16-127
A study to learn how well and safe a medicine containing glecaprevir and pibrentasvir works to treat adult patients with long-lasting hepatitis-C infection and kidney damage
Hepatitis C virus

Trial dates:
Mar 2017 – Jun 2018

Last modified:
May 2019

Available languages:
EnglishGerman, Italian, Korean, Polish, Spanish

M16-133    
A study to learn how effective and safe a medicine containing glecaprevir and pibrentasvir works to treat adult patients with long-lasting hepatitis C infection who had never been treated before and had no liver cirrhosis (scarring of the liver) based on the result of the APRI blood test Hepatitis C virus

Trial dates:
Aug 2017 – Aug 2018

Last modified:
Sep 2019

Available languages:
Bulgarian, English, German, Polish, Russian, Spanish

M16-135    
A study to learn how effective and safe a medicine containing glecaprevir and pibrentasvir works to treat adult patients with long-lasting hepatitis C genotypes 1–6 infection with scarring of the liver who have not been treated before Hepatitis C virus

Trial dates:
Apr 2017 – Nov 2019

Last modified:
Oct 2020

Available languages:
English, Bulgarian, Czech, Romanian, Russian, Spanish

Immunology

Study ID/Title Condition Description
M11-327
A study to learn how well and safe long-term use of a medicine called adalimumab works to treat adult patients with non-infectious intermediate uveitis, posterior uveitis, or panuveitis Uveitis

Trial dates:
Dec 2010 – May 2018

Last modified:
Jul 2019

Available languages:
EnglishGermanItalian,
JapanesePolishSpanish

M14-033    
A study to learn how effective and safe higher doses of the study drug adalimumab is for patients with ulcerative colitis Ulcerative colitis

Trial dates:
Mar 2014 - Nov 2019

Last modified:
Oct 2020

Available languages:
English, Dutch, Italian, Spanish, Japanese, Polish, Ukrainian

M14-500 
A study to learn if clinical disease activity measured by Magnetic Resonance Imaging (MRI) helped predict flares in adult patients with rheumatoid arthritis in remission who were being treated with dose-tapered adalimumab
Rheumatoid arthritis

Trial dates:
Jan 2015 – Aug 2018

Last modified:
Oct 2019

Available languages:
EnglishGermanItalian
Spanish

M15-574
A study to learn how effective and safe the study drug adalimumab is for patients with hidradenitis suppurativa Hidradenitis suppurativa

Trial dates:
Jul 2016 - Oct 2019

Last modified:
Aug 2020

Available languages:
EnglishDutchGerman, Greek, Spanish, Turkish

M15-989
A study to learn how safe a medicine containing the study drug risankizumab is for patients with moderate to severe Crohn's disease Crohn's Disease

Trial dates:
Sep 2015 – Jun 2019

Last modified:
May 2020

Available languages:
English, Dutch, Korean, Spanish, German, Polish

M15-992 
A study to learn how effective and safe a medicine containing the study drug risankizumab is compared to placebo (no medicine) to treat adult patients with moderate to severe long-lasting plaque psoriasis after initial treatment, withdrawal, relapse, and re-treatment Psoriasis

Trial dates:
Feb 2016 – Jul 2018

Last modified:
Sep 2019

Available languages:
English, French, French Canadian, German, Japanese, Korean

M16-004 
A study to learn how effective and safe a medicine containing the study drug risankizumab works compared to placebo (no medicine) to treat adult Japanese patients with moderate to severe long-lasting plaque psoriasis Psoriasis

Trial dates:
Dec 2016 – Jun 2018

Last modified:
Aug 2019

Available languages:
English, Japanese

M16-009
A study to learn how effective and safe a medicine containing the study drug risankizumab works to treat adult patients with moderate to severe long-lasting plaque psoriasis

Psoriasis

Trial dates:
Nov 2014 – Sep 2018

Last modified:
Jul 2019

Available languages:
EnglishFrenchFrench CanadianGerman

M16-048
A study to learn how safe and effective a medicine containing the study drug upadacitinib works compared to placebo (no medicine) to treat adult patients with moderate to severe atopic dermatitis Atopic dermatitis

Trial dates:
Oct 2016 – Jan 2019

Last modified:
Apr 2020

Available languages:
English, Finnish, Dutch, Japanese, German

M16-178
A study to learn how effective and safe a medicine containing the study drug risankizumab works compared to the study drug FUMADERM® to treat adult patients with moderate to severe plaque psoriasis Psoriasis

Trial dates:
Aug 2017 – Jul 2018

Last modified:
Jul 2019

Available languages:
EnglishGerman

M16-244  

 

A study to learn how safe and effective a medicine containing the study drug risankizumab is for adult patients with psoriatic arthritis Psoriatic arthritis

Trial dates:
Dec 2016 – Jul 2018

Last modified:
May 2020

Available languages:
EnglishCzech, Finnish, Japanese, Polish, Spanish

Oncology

Study ID/Title Condition Description
M14-361  
A study to learn how effective and safe a medicine containing veliparib works to treat adult patients with advanced small cell lung cancer in combination with carboplatin and etoposide Lung cancer

Trial dates:
Oct 2014 - Apr 2019

Last modified:
Apr 2020

Available languages:
English, Russian, Dutch, Hungarian, Spanish, Korean

Neuroscience

Study ID/Title Condition Description
M15-535  
A study to learn how effective and safe a medicine containing levodopa-carbidopa is compared to current standard patient medication to treat dyskinesia in adult patients with advanced idiopathic Parkinson's disease Parkinson's Disease

Trial dates:
Feb 2017 - Sep 2019

Last modified:
Jul 2020

Available languages:
English, Italian, Finnish, Slovak, Greek, Spanish